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Effect of cyclosporine administration on renal hemodynamics in con-
scious rats. The effect of acute and chronic administration of
cyclosporine on systemic and renal hemodynamics was studied in
conscious rats. Infusion of cyclosporine in a dose of 20 mg/kg (Cy 20)
resulted in a significant fall in renal blood flow (RBF) (3.4 vs. 6.5
ml/min/g, P < 0.05) and a rise in renal vascular resistance (RVR) (36.9
vs. 20.6mm Hg/mI/minlg, P < 0.05). Infusion of cyclosporine at a dose
of 10 mg/kg (Cy 10) did not result in a significant change in RBF or
RVR. Both doses of cyclosporine resulted in stimulation of plasma
renin activity (PRA) from control values of 5.6 0.8 ng/ml/hr to 11.6
2.0 with 10 mg/kg and 26.7 5.6 with 20 mg/kg. Urinary 6-keto-PGF1,,
excretion increased from control values of 14.0 2.0 ng/6hr to 22.7
2.2 with 10mg/kg and 25.0 2.0 with 20mg/kg. Similar effects on RBF,
RVR, PRA, and 6-keto-PGF1,, excretion were seen after chronic
administration of cyclosporine (20 mg/kg i.p. for 7 days). Pretreatment
of animals with captopril did not prevent the fall in RBF after
cyclosporine, suggesting that the vasoconstriction was not mediated by
angiotensin H. Animals treated with meclofenamate demonstrated
reduction in RBF with 10 mg/kg cyclosporine (4.3 vs. 7.0 ml/min/g, P <
0.05), suggesting that prostaglandins protect against the vasoconstrictor
effect of cyclosporine. Administration of phenoxybenzamine after
cyclosporine improved RBF (5.0 vs. 3.4 ml/min/g) and restored RVR to
normal. Similarly, renal denervation dramatically reduced the fall in
RBF after cyclosporine (innervated right kidney 3.6 vs. denervated left
kidney 6.0 mllminlg, P < 0.001). We conclude that cyclosporine causes
renal vasoconstriction, which is mediated by the renal sympathetic
nervous system, and that vasoconstriction is exacerbated by the
administration of cyclooxygenase inhibitors.
Effet de l'administration de cyclosporine sur l'hémodynamique rénale
de rats éveillés. L'effet d'une administration aigue ou chronique de
cyclosporine sur l'hémodynamique systCmique ou rénale a été étudié
chez des rats 6veillës. Une perfusion de cyclosporine a Ia dose de 20
mg/kg (Cy 20) a entraInè une chute significative du debit sanguin renal
(RBF) (3,4 vs. 6,5 ml/min/g, P < 0,05) et une élCvation des resistances
vasculaires rénales (RVR) (36,9 vs. 20,6 mm Hg/ml/min/g, P < 0,05).
Une perfusion de cyclosporine a Ia dose de 10 mg/kg (Cy 10) n'a pas
modifle significativement RBF ni RVR. Les deux doses de cyclosporine
ont stimulé l'activitC rénine plasmatique (PRA) de valeurs contrôles de
5,6 0,8ng/mllhrall,6 2,Oavec 10mg/kg, età26,7 5,6 avec 20
mg/kg. L'excrétion urinaire de 6-céto-PGF1,, a augmentC de valeur
contrôle de 14,0 2,0 ng/6 hr a 22,7 2,2 avec 10mg/kg, et 25,0 2,0
avec 20 mg/kg. Des effets identiques sur RBF, RVR, PRA et excretion
de 6-cCto-PGF1, ont ete observes apres administration chronique de
cyclosporine (20 mg/kg ip, pendant 7 jours). Le prétraitement des
animaux avec du captopril n'a pas empeche la chute de RBF après
cyclosporine, cc qui suggére que Ia vasoconstriction n'Ctait pas médiée
par l'angiotensine II. Les animaux traités avec du méclofénamate ont
prCsenté une reduction de RBF avec 10 mg/kg de cyclosporine (4,3 vs.
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7,0 ml/min/g, P < 0,05) cc qui suggère que Ia prostaglandine protege des
effets vasoconstricteurs de Ia cyclosponne. L'administration de
phénoxybenzamine après la cyclosporine a amélioré RBF (5,0 vs. 3,4
ml/min/g) et a ramené RVR a Ia normale. Dc méme, Ia dCnervation
rénale a réduit de facon marquee Ia chute de RBF aprCs la cyclosporine
(rein droit innervC 3,6 contre rein gauche dCnervé 6,0 ml/min/g, P <
0,001). Nous concluons que Ia cyclosporine entraIne une vasoconstric-
tion rCnale, qui est médiCe par Ic système nerveux sympatique renal, et
que cette vasoconstriction est exacerbCe par l'administration des
inhibiteurs de la cyclohoxygénase.
Cyclosporine has become increasingly popular as the im-
munosuppressive of choice for renal, cardiac, pancreatic, and
hepatic transplantation [1—5]. However, one of the major fac-
tors limiting its use is nephrotoxicity. A number of adverse
effects of cyclosporine on renal function have been described.
These include a reversible, dose-dependent increase in serum
creatinine [6], hyperkalemia [7, 8], metabolic acidosis [9],
hypertension [1—3], and chronic interstitial nephritis with irre-
versible deterioration in renal function [10]. The exact mecha-
nisms involved in these toxic effects of cyclosporine on the
kidney are not fully understood, although they may reflect
tubular toxicity, especially in the straight segment of the
proximal tubule [11]. However, the possibility that
cyclosporine may affect renal blood vessels has recently been
raised [121. A decrease in the "renal perfusion index" derived
from nuclear medicine studies following CSA administration to
humans [13] and a vascular lesion thought to be specific for
cyclosporine have been described [14]. Recently, Powell-Jac-
kson et al described a syndrome in liver transplant recipients
receiving intravenous cyclosporine characterized by oliguria
and a low fractional excretion of sodium [15]. These findings
suggest that cyclosporine may have a direct effect on the renal
circulation. We, therefore, studied the effects of acute and
chronic administration of cyclosporine on renal blood flow in
the rat and examined several systems controlling the renal
circulation, namely, the renin-angiotensin, prostaglandin, and
the sympathetic nervous systems.
Methods
Male Sprague-Dawley rats (Harlan, Madison, Wisconsin,
USA) 250 to 350 g in weight were maintained on Purina rat
chow and tap water ad lib. Cyclosporine (provided by Sandoz
Pharmaceuticals, East Hanover, New Jersey, USA) was pre-
pared by dissolving in ethanol and then diluting with 10% fat
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emulsion (Intralipid, Miles Labs, Berkeley, California, USA) to
give a solution containing 5 to 10 mg/mi of cyclosporine.
Effect of cyclosporine infusion on systemic and renal
hemodynamics
Rats were anesthetized briefly with ether, and polyethylene
cannulas (PE-S0) were inserted into the femoral artery, vein and
the left ventricle via the right carotid artery. Volume replace-
ment was given as 0.5% of body wt as isotonic saline. Rats were
placed in acrylic restrainers and allowed 45 mm to recover from
anesthesia. The following groups were studied: Group I (N = 8)
received an infusion of the fat emulsion vehicle only. Group II
(N = 8) received an infusion of cyclosporine (10 mg/kg), and
Group III (N = 6) received cyclosporine (20 mg/kg). The
infusions were given at the rate of 0.034 mI/mm through the
femoral vein catheter. Thirty mm after the end of the infusion,
systemic and renal hemodynamics were measured using
radiolabelled microspheres [16]. The microspheres used were 9
0.7 in diameter and labelled with 85Sr. Mean arterial
pressure (MAP) was monitored using a pressure transducer
(P23D6, Gould Statham Inc., San Juan, Puerto Rico) connected
to a chart recorder (Hewlett Packard 7702B, Elkhart, Indiana,
USA). Cardiac output was expressed as cardiac index by
correcting for body wt in kilograms. Renal blood flow was
corrected for kidney wt in g.
Effect of cyclosporine infusion on plasma renin activity (PRA)
and urinary prostaglandins
Plasma renin activity was determined by radioimmunoassay
[17] at pH 5.7 using a commercially available kit (New England
Nuclear, Boston, Massachusetts). Samples of heparinized
plasma were obtained from the femoral arteries of conscious
rats 15 mm after intravenous administration of cyclosporine (20
mg/kg), cyclosporine (10 mg/kg) and vehicle, and before injec-
tion of microspheres. To determine the effect of cyclosporine
infusions on prostaglandin excretion, three separate groups of
rats received either the vehicle (N = 10), cyclosporine 10 mg/kg
(N 8), or cyclosporine 20 mg/kg (N = 8). At the conclusion of
the infusions, the rats were given 2 ml of 5% dextrose by vein
to ensure adequate urine flow, placed in metabolic cages and
their urine collected for 6 hrs. PGE2 and 6-keto-PGF1a in the
urine were measured by radioimmunoassay [18].
Effect of captopril on the renovascular response to
cyclosporine infusion
Thirteen rats were given captopnl (Squibb, Princeton, New
Jersey, USA), 50 mg/kg i.v., 15 mm after insertion of vascular
catheters and allowed a further 30 mm to recover. Group IV (N
= 7) then received an infusion of the vehicle, while Group V (N
= 6) received cyclosporine (20 mg/kg). Thirty mm after com-
pletion of the infusion, systemic and renal hemodynamics were
measured.
Effect of meclofenamate on the renovascular response to
cyclosporine infusion
Fourteen rats were given meclofenamate, 5 mg/kg i.v., 15 mm
after insertion of vascular catheters and allowed a further 30
mm to recover. Group VI (N = 6) then received an infusion of
the vehicle, while Group VII (N = 8) received cyclosporine (10
mg/kg). Thirty mm after completion of the infusion, systemic
and renal hemodynamics were measured.
Effect of phenoxybenzamine on the renovascular response to
cyclosporine infusion
Fourteen rats were prepared for microsphere study as out-
lined previously. Group VIII (N = 8) received an infusion of the
vehicle 45 mm after surgery, while Group IX (N = 6) received
cyclosporine (20 mg/kg). Fifteen mm after completion of the
infusion, both groups were given an intravenous injection of the
a-adrenengic blocker, phenoxybenzamine, 1 mg/kg in 5% dex-
trose. Fifteen mm later, mean arterial pressure was recorded
and systemic and renal hemodynamics were measured.
Effect of renal denervation on the renovascular response to
cyclosporine
Twelve rats underwent unilateral denervation of the left renal
artery, accomplished by exposing the renal nerve and painting
it with 10% phenol. Three days later the rats were divided into
two groups and prepared for microsphere study. Group X (N =
6) received an infusion of the vehicle while Group XI (N =6)
received an infusion of cyclosporine 20 mg/kg. Thirty mm after
completion of the infusions, systemic and renal hemodynamics
were measured.
Effect of chronic cyclosporine administration on renal
hemodynamics
Rats housed in individual metabolic cages received daily
intraperitoneal injections of cyclosporine (20 mg/kg) in 10% fat
emulsion (N = 6) or vehicle alone (N = 6). Because preliminary
experiments revealed that this dose of cyclosporine resulted in
decreased food intake, cyclosporine and control rats were
pair-fed. Urine was collected daily for measurement of
prostaglandin excretion. After 1 week the rats were prepared as
above for study of renal hemodynamics. Shortly before
microsphere injection, 0.5 ml of whole blood was obtained for
measurement of PRA and plasma creatinine. This blood was
replaced with an equivalent volume of normal saline.
Statistical analysis
All data are expressed as mean standard error. Multiple
groups were compared using one-way analysis of variance and
the studentized range test was then used for intergroup com-
parisons. Comparisons of only two groups were made by
unpaired t test, with the exception of the renal denervation
studies where differences in blood flow between right and left
kidneys were tested by paired t test.
Results
Effect of cyclosporine infusion on systemic and renal
hemodynamnics
Infusion of cyclospormne in a dose of 20 mg/kg resulted in a
slight fall in MAP, but no changes in cardiac index (CI) or
systemic vascular resistance (SVR) (Table 1). Nevertheless,
there was a marked decrease in renal blood flow and a rise in
renal vascular resistance (Fig. 1). When given in a lower dose of
10 mg/kg, there was no change in MAP, CI, or SVR. Although
there was a trend toward a lower renal blood flow and higher
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Group
MAP
mm Hg
CI
mI/mm/kg
SVR
mm Hg/mI/mm kg
I Control 126 3 418 27 0.29 0.01
(N=8)
II Cy 10 126 3 430 9 0.29 0.01
(N = 8)
11120 114 3 405 64 0.31 0.05
(N = 8)
P value
Ivs.II NS NS NS
I vs. III <0.05 NS NS
11 vs. III <0.05 NS NS
renal vascular resistance, these changes were not statistically
significant.
Effect of cyclosporine infusion on PRA and renal
prostaglandin excretion
Both doses of cyclosporine resulted in a dose-dependent
activation of the renin-angiotensin system (Fig. 2). Similarly,
infusion of cyclosporine resulted in an increase in urinary
excretion of 6-keto-PGF1a (Fig. 3) while excretion of PGE2 was
not significantly increased (data not shown). After treatment
with meclofenamate, plasma renin levels were suppressed in
both control and cyclosporine (10 mg/kg)-treated animals, but
PRA remained significantly higher in the cyclosporine-treated
animals than in controls (6.6 0.6 vs. 2.5 0.4 ng mllhr, P <
0.01).
Effect of captopril on the response to cyclosporine infusion
To investigate the role of the renin-angiotensin system in the
decreased renal blood flow after cyclosporine, rats were pretre-
ated with the converting enzyme inhibitor, captopril, before
receiving either cyclosporine or vehicle. This dose of captopril
resulted in greater than 90% inhibition of the pressor response
to angiotensin I. After captopril, cyclosporine infusion still
caused a fall in RBF and a rise in RVR (Table 2). This suggests
that the decrease in RBF following cyclosporine infusion was
not mediated by angiotensin II.
Effect of meclofenamate on the response to cyclosporine
infusion
To investigate the role of prostaglandins in maintaining renal
blood flow following cyclosporine infusion, we pretreated rats
with meclofenamate to inhibit prostaglandin synthesis.
Cyclosporine was then given in a dose (10 mg/kg) that did not
cause a fall in renal blood flow in prostaglandin-intact rats.
Control animals received meclofenamate and vehicle only.
Meclofenamate did not significantly affect RBF in control
animals (Table 3). On the other hand, cyclosporine decreased
renal blood flow and raised renal vascular resistance in rats with
prostaglandin inhibition.
Effect of phenoxybenzamine on the renovascular response to
cyclosporine infusion
To investigate a possible role of increased renal or circulating
catecholamines in the renovascular response to cyclosporine,
phenoxybenzamine was administered to rats who had received
infusions of either cyclosporine (20 mg/kg) or vehicle. The dose
of phenoxybenzamine used, 1 mg/kg, reduced the pressor effect
of norepinephrine by greater than 90%. In both the control and
cyclosporine-treated animals, phenoxybenzamine lowered
mean arterial pressure and systemic vascular resistance (Table
4). In control animals, there was a small, nonsignificant fall in
renal blood flow, but renal vascular resistance was no different
from control animals not given phenoxybenzamine. On the
other hand, phenoxybenzamine increased renal blood flow in
cyclosporine-treated rats so that it was not significantly dif-
ferent from that of phenoxybenzamine-treated controls. Fur-
thermore, phenoxybenzamine decreased renal vascular resist-
ance to normal values in cyclosporine-infused animals.
Effect of renal denervation on renovascular response to
cyclosporine infusion
Table 5 summarizes the effect of renal denervation on the
renovascular response to cyclosporine (20 mg/kg). Denervation
of the left kidney did not significantly affect renal blood flow in
control animals. On the other hand, in cyclosporine-treated
animals, a significant fall in renal blood flow occurred only in
the intact innervated right kidney. Renal blood flow in the
denervated left kidney was not different from controls. There-
fore, renal denervation prevented the cyclosporine-induced
decrease in renal blood flow and increase in renal vascular
resistance.
Effect of chronic cyclosporine administration
Table 6 summarizes the results of hemodynamic studies in
rats given cyclosporine, 20 mg/kg daily, for 1 week. Mean
arterial pressure was slightly lower in cyclosporine-treated
animals compared to controls, but there was no significant
difference in cardiac index or systemic vascular resistance.
Cyclosporine-treated animals had lower renal blood flow and
higher renal vascular resistance compared to pair-fed control
animals. This fall in blood flow was specific for the kidney,
since liver blood flow (hepatic arterial blood flow) was not
significantly different between control and cyclosporine-treated
animals (control 0.53 0.12 vs. cyclosporine 0.83 0.21
mllmin/g; NS). Chronic administration of cyclosporine, like
acute infusion of cyclosporine, caused stimulation of both PRA
and 24-hr urinary excretion of 6-keto-PGF1a (Table 7). Finally,
cyclosporine-treated animals also had evidence of decreased
glomerular filtration since plasma creatinine levels were higher
and creatinine clearance values lower than in controls (Table 8).
Discussion
Since the introduction of cyclosporine in human transplanta-
tion in 1976, nephrotoxicity has been a recurrent and worrisome
problem [19, 20]. A number of studies have examined
cyclosporine nephrotoxicity in rats and several investigators
have found decreases in glomerular filtration rate after chronic
[11, 21] or acute [22] administration of cyclosporine. However,
few direct measurements of renal blood flow have been made in
Table 1. Effect of cyclosporine infusion on systemic hemodynamics
Abbreviations are: MAP, mean arterial pressure; CI, cardiac index;
SYR, systemic vascular resistance; Cy 10, cyclosporine 10 mg/kg; Cy
20, cyclosporine 20 mg/kg.
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Fig. 1. Effect of cyclosporine infusion on renal
hemodynamics. Abbreviations are: Cy 10,
cyclosporine 10 mg/kg; Cy 20, cyclosporine 20
mg/kg; NS, not significantly different. Numbers
inside bars are number of animals.
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reported. Since tubular handling of PAH is impaired by
cyclosporine [10], PAH clearance must be adjusted for the
reduced extraction to obtain an accurate assessment of renal
perfusion. Myers et al found decreased renal plasma flow in
heart transplant recipients after 1 year of cyclosporine therapy,
but this occurred at a time when histologic damage was present
[10]. From this data, it is difficult to know if the effects of
Control Cy 10 Cy 20
Fig. 2. Effect of cyclosporine infusion on plasma renin activity.
Control Cy 10 Cy 20
of cyclosporine infusion on urinary excretion of
either humans or animals receiving cyclosponne. Siegi et al,
using the clearance of PAH, reported decreased renal plasma
flow in the spontaneously hypertensive rat after cyclosporine
[23], although the actual magnitude of this effect was not
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Table 2. Effect of cyclosporine on systemic and renal hemodynamics after captopril
MAP CI SYR RBF
Group mm Hg ml/min/kg mm Hg/ml/min kg ml/min/g
RVR
mm Hg/mi/mm g
I Control 126 3 418 27 0.29 0.01 6.5 0.6 20.6 1.9(N=8)
IV Control + captopril 113 3 393 12 0.28 0.01 7.1 0.4 15.9 0.8(N = 6)
III Cy 20 mg/kg 114 3 405 64 0.31 0.05 3.4 0.4 36.9 5.6(N = 6)
V Cy 20 mg/kg + captopril 103 3 361 25 0.29 0.01 4.2 0.6 27.6 3.2(N = 7)
P value
I vs. III <0.05 NS NS <0.05 <0.05
I vs. V <0.05 NS NS <0.05 NS
IV vs. V NS NS NS <0.05 NS
Abbreviations are: RBF, renal blood flow; RVR, renal vascular resistance.
Table 3. Effect of cyclosporine on systemic and renal hemodynamics after meclofenamate
MAP CI SVR RBF RVR
Group mm Hg mI/mm/kg mm Hg mI/mm kg ml/min/g mm Hg/mi/mm g
I Control 126 3 418 27 0.29 0.01 6.5 0.6 20.6 1.9(N=8)
VI Control + meclofenamate 126 3 402 22 0.32 0.02 7.0 0.5 18.7 1.9(N = 6)
II Cy (10 mg/kg) 126 2 430 0 0.28 0.01 5.3 0.5 23.9 1.9(N = 8)
VII Cy (10 mg/kg) + meclofenamate 117 4 374 22 0.32 0.02 4.3 0.4 28.0 1.9(N=8)
P value
I vs. II NS NS NS NS NS
I vs. VII NS NS NS <0.05 <0.05
VI vs. VII NS NS NS <0.05 <0.05
Table 4. Effect of cyclosporine on systemic and renal hemodynamics after phenoxybenzamine
MAP CI SVR RBF RVR
mm Hg mI/mm/kg mm Hg mi/mm kg ml/min/g mm Hg mi/mm g
I Control 126 3 418 27 0.29 0.01 6.5 0.6 20.6 1.9(N = 8)
VIII Control + POB 99 4 514 34 0.20 0.01 5.4 0.4 18.6 1.1(N = 8)
III Cy 20mg/kg 114 3 405 64 0.31 0.05 3.4 0.4 36.9 5.6(N = 6)
IX Cy 20mg/kg 89 4 496 15 0.18 0.01 5.0 0.5 18.8 1.5(N = 6) + POB
P value
I vs. III NS NS NS <0.05 <0.05
I vs. IX <0.05 NS <0.05 NS NS
VIII vs. IX NS NS NS NS NS
Abbreviation: POB, phenoxybenzamine.
cyclosporine on RBF are direct or occur only after there has
been renal tubular damage. In the present study, we found a
marked decrease in renal blood flow following both the acute
infusion of cyclosporine and 1 week of chronic administration
to rats. The rapidity with which these changes were seen after
cyclosporine infusion suggests that renal vasoconstriction is a
primary effect of cyclosponne.
The renin-angiotensin system was activated in rats given
cyclosporine both acutely and chronically (Fig. 2 and Table 7)
in agreement with other investigators [24, 25]. Baxter et al have
recently shown that cyclosporine can stimulate renin release
from cortical slices incubated in vitro [26]. To investigate the
possibility that increased angiotensin II might mediate the renal
vasoconstriction seen after acute cyclosporine infusion, we
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Table 5. Effect of unilateral renal artery denervation on the renovascular response to cyclosporine infusion
Group
RBF RVR
m!/min/g mm Hg/mi/mm g
MAP CI SVR RK LK RK LK
mm Hg mi/rn/n/kg mm Hg/mi/mm kg innervated denervated innervated denervated
X Control
(N=6)
XI Cy 20
(N = 6)
122 3 423 14 0.29 .01 7.5 .09 7.5 .09 17.1 1.6 17.3 1.9
105 5 392 30 0.27 .01 3.6 0.6 6.0 0.7 32.3 5.0 18.3 1.9
P<O.001 P<0.005
p value <0.05 NS NS <0.01 NS <0.01 NS
Table 6. Effect of chronic cyclosporine administration on systemic and renal hemodynamics
MAP CI SVR RBF RVR
mm Hg mI/mm/kg mm Hg/mI/mm kg mi/minlg mm Hg/mi/rn/n g
Control
(N=6)
Cyclosporine(N = 6)
132 3 367 20 0.38 0.02 5.4 0.4 26.4 2.4
120 4 355 44 0.37 0.04 3.0 0.5 48.1 8.3
P value <0.05 NS NS <0.01 <0.05
Table 7. Effect of chronic cyclosporine administration on plasma
renin activity and urinary prostaglandins
Group
PRA
ng mi/hr
6-keto-PGF1
ng/24 hr
PGE2
ng/24 hr
Control
(N=6)
Cyclosporine(N = 6)
8.4 1.9
24.0 6.6
58.6 8.2
107.7 17.3
118.7 10.4
78.7 11.5
P value <0.05 <0.05 NS
Table 8. Effect of chronic cyclosporine administration on plasma
creatinine and creatinine clearance
Group
Plasma creatinine
mg/dl
Creatinine clearance
mi/mm
Control 0.34 .03 2.09 .12
(N = 6)
Cyclosporine 0.53 .05 1.20 .11(N = 6)
P value <0.01 <0.01
treated animals with captopril before administering a dose of
cyclosporine, known to cause renal vasoconstriction. Captopril
did not prevent the decrease in renal blood flow caused by
cyclosporine, suggesting that activation of the renin-angiotensin
system was probably the result, rather than the cause, of
decreased renal perfusion.
Acute and chronic administration of cyclosporine to rats
resulted in increased urinary excretion of 6-keto-PGF1a (Fig. 3
and Table 7). Increased urinary excretion of 6-keto-PGF1c. has
also been seen in other conditions characterized by renal
hypoperfusion and increased renin secretion. It has been pos-
tulated that the role of increased prostacyclin production in
these states is to maintain renal blood flow and stimulate renin
secretion [27]. To investigate whether prostacyclin might have
a protective effect in cyclosporine-mediated renal vasoconstric-
tion, we treated rats with meclofenamate prior to cyclosporine
infusion. The dose of cyclosporine used for this experiment, 10
mg/kg, did not cause a significant decrease in RBF in
prostaglandin-intact animals, although it did increase 6-keto-
PGFic. excretion (Fig. 3). Following meclofenamate, cyclospor-
me in this dose decreased renal blood flow, suggesting that
prostaglandin production attenuates cyclosporine-induced renal
vasoconstriction. It also suggests that the use of cyclooxygen-
ase inhibitors in patients receiving cyclosporine could exacer-
bate the toxic effects of this drug on the kidney.
Stimulation of the renal sympathetic nervous system can
result in renal vasoconstriction and stimulation of renin produc-
tion [28]. To test the possibility that renal vasoconstriction in
response to cyclosporine might be mediated by increased levels
of circulating catecholamines or increased renal nerve activity,
we administered the a-adrenergic blocker, phenoxybenzamine,
to rats infused with cyclosporine. Phenoxybenzamine did not
affect renal blood flow or vascular resistance in control animals.
However, in cyclosporine-treated animals, phenoxybenzamine
increased renal blood flow and prevented an increase in renal
vascular resistance (Table 4). These findings suggest that the
renal vasoconstriction after cyclosporine infusion is mediated
by catecholamines.
To define the role of the sympathetic nervous system further,
we studied the effect of renal denervation on the renovascular
response to cyclosporine. We elected to denervate only the left
kidney so that the contralateral right kidney would serve as a
paired control. In the control animals receiving vehicle,
denervation did not affect renal blood flow (Table 5). However,
in the animals infused with cyclosporine, significant vasocon-
striction occurred only in the innervated right kidney. In the
denervated left kidney, renal blood flow and vascular resistance
were not significantly different from controls. Therefore, renal
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vasoconstriction following cyclosporine infusion was mediated
through increased renal nerve activity.
Primary renal vasoconstriction could result in the decreased
glomerular filtration rate (GFR) seen after acute cyclosporine
infusion [22]. However, Whiting et al [11] have proposed that
primary tubular injury results in activation of the tubuloglomer-
ular feedback (TGF) mechanism with a secondary fall in renal
blood flow and GFR. We do not believe that such a mechanism
explains the decreased renal blood flow seen in our studies, The
renal nerves are not felt to mediate tubuloglomerular feedback
[29], yet renal denervation completely corrected the decrease in
renal blood flow seen after cyclosporine infusion. Also,
Diepirink, Starklint, and Leyssac found that in rats given
cyclosporine chronically, proximal tubular sodium reabsorption
was enhanced and distal delivery of sodium decreased [21].
Increased, rather than decreased, distal sodium delivery would
be required to stimulate tubuloglomerular feedback. Our stud-
ies, however, do not prove that a fall in glomerular filtration rate
after cyclosporine is due solely to decreased renal blood flow.
Restoration of renal blood flow might not completely restore
glomerular filtration rate to normal if cyclosporine also had
effects on the glomerular ultrafiltration coefficient, for example.
Most studies of cyclosporine nephrotoxicity to date have
focused on its tubular toxicity with little attention being paid to
its effect on the renal vasculature. While extrapolation from the
rat to humans is hazardous, our findings may be relevant to
certain aspects of cyclosporine nephrotoxicity in humans. The
closest parallel in humans is the occurrence of acute renal
dysfunction following heart or liver transplantation [15, 30].
Acute onset of oliguria and increased creatinine have been seen
within a few days of transplantation in the absence of identifi-
able prerenal or postrenal causes. In this setting, urinary
sodium excretion is generally low, suggesting intact tubular
function, and PRA levels are elevated. This syndrome has been
seen most commonly when cyclosporine was administered
intravenously [15]. Our findings strongly support the hypothesis
that this syndrome is the result of cyclosporine-induced renal
vasoconstriction. Such hypoperfusion, if prolonged, could also
result in acute tubular necrosis or slow recovery from postop-
erative acute renal failure.
The relevance of these studies to cyclosporine nephrotoxicity
in human renal transplants is less clear. Initially, the renal
allograft is denervated, so that any vasoconstriction in the early
post-transplant period would have to be mediated by circulating
catecholamines. However, there is evidence that grafts begin to
reinnervate within 1 month, and that innervation is extensive by
5 months [31]. Patients treated with cyclosporine also have
higher serum creatinine levels than patients treated with con-
ventional immunosuppression, and switching patients from
cyclosporine to azathioprine results in a prompt fall in creati-
nine levels in the absence of superimposed rejection [32].
Furthermore, in the first 6 months after transplant, cyclosporine
nephrotoxicity is not characterized by any particular histologi-
cal finding [6, 33]. Renal vasoconstriction by cyclosporine could
account for this functional renal failure. Further studies will be
required to define the role of the sympathetic nervous system in
chronic cyclosporine nephrotoxicity and whether cx-adrenergic
blocking agents such as prazosin are helpful in limiting the
nephrotoxic effects of cyclosporine.
In summary, both acute and chronic administration of
cyclosporine in rats resulted in increased renal vascular resist-
ance. Plasma renin activity and urinary 6-keto-PGF1a were
increased following cyclosporine, but angiotensin II was not the
cause of the renal vasoconstriction. Prostaglandin synthesis
inhibitors potentiated cyclosporine-induced renal vasoconstric-
tion. Cyclosporine was found to produce renal vasoconstriction
by activation of the sympathetic nervous system via the renal
nerves since either phenoxybenzamine or renal denervation
prevented cyclosporine-mediated decreases in renal blood flow
and increases in renal vascular resistance.
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